

REFERENCES

- Amengual, O., Atsumi, T., Khamashta, M.A. & Hughes, G.R.V. (1998) The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. *Thrombosis and Haemostasis*, **79**, 276–281.
- Arnout, J., Wittevrongel, C., Vanrusselt, M., Hoylaerts, M. & Vermynen, J. (1998) β 2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody β 2-glycoprotein I complexes on phospholipid surfaces. *Thrombosis and Haemostasis*, **79**, 955–988.
- Atsumi, T., Khamashta, M.A., Haworth, R.S., Brooks, G., Amengual, O., Ichikawa, K., Koike, T. & Hughes, G.R.V. (1998a) Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. *Arthritis and Rheumatism*, **41**, 800–807.
- Atsumi, T., Khamashta, M., Amengual, O., Donohoe, S., Mackie, I., Ichikawa, K., Koike, T. & Hughes, G. (1998b) Binding of anticardiolipin antibodies to protein C via β 2-glycoprotein I (β 2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. *Clinical and Experimental Immunology*, **112**, 325–333.
- Bancsi, L.F., van der Linden, I.K. & Bertina, R.M. (1992) β 2-glycoprotein I deficiency and the risk of thrombosis. *Thrombosis and Haemostasis*, **67**, 649–653.
- de Benedetti, E., Reber, G., Miescher, P.A. & de Moerloose, P. (1992) No increase of β 2-glycoprotein I levels in patients with antiphospholipid antibodies. *Thrombosis and Haemostasis*, **68**, 624.
- Del PaPa, N., Guidali, L., Sala, A., Buccellati, C., Khamashta, M.A., Ichikawa, K., Koike, T., Balestrieri, G., Tincani, A., Hughes, G.R.V. & Meroni, P.L. (1997) Endothelial cells as target for antiphospholipid antibodies. *Arthritis and Rheumatism*, **40**, 551–561.
- Galli, M., Cortelazzo, S., Daldossi, M. & Barbui, T. (1992) Increased levels of beta 2-glycoprotein I (aca-Cofactor) in patients with lupus anticoagulant. *Thrombosis and Haemostasis*, **67**, 386.
- Gurewich, V., Johnstone, M., Loza, J. & Pannell, R. (1993) Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. *FEBS*, **318**, 317–321.
- Hashimoto, Y., Kawamura, M., Ichikawa, K., Suzuki, T., Sumida, T., Yoshida, S., Matsuura, E., Ikehara, S. & Koike, T. (1992) Anticardiolipin antibodies in NZW x BXSb F1 mice. A model of antiphospholipid syndrome. *Journal of Immunology*, **149**, 1063–1068.
- Henry, M.L., Everson, B. & Ratnoff, O.D. (1988) Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I. *Journal of Laboratory and Clinical Medicine*, **111**, 519–523.
- Hughes, G.R.V. (1993) The antiphospholipid syndrome: ten years on. *Lancet*, **342**, 341–344.
- Ichikawa, K., Khamashta, M., Koike, T., Matsuura, E. & Hughes, G. (1994) Beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. *Arthritis and Rheumatism*, **37**, 1453–1461.
- Ichinose, A., Fujikawa, K. & Suyama, T. (1986) The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. *Journal of Biological Chemistry*, **261**, 3486–3489.
- Ieko, M., Ichikawa, K., Triplett, D.A., Matsuura, E., Atsumi, T., Sawada, K. & Koike, T. (1999) Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. *Arthritis and Rheumatism*, **42**, 167–174.
- Igarashi, M., Matsuura, E., Igarashi, Y., Nagae, H., Ichikawa, K., Triplett, D.A. & Koike, T. (1996) Human β 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. *Blood*, **87**, 3262–3270.
- Khamashta, M.A. & Hughes, G.R.V. (1995) Antiphospholipid antibodies and antiphospholipid syndrome. *Current Opinion in Rheumatology*, **7**, 389–394.
- Kluft, C. (1979) Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. *Thrombosis and Haemostasis*, **41**, 365–383.
- Kluft, C., Dooijewaard, G. & Emeis, J. (1987) Role of the contact system in fibrinolysis. *Seminars in Thrombosis and Hemostasis*, **13**, 50–68.
- Koike, T. & Matsuura, E. (1999) Immunology of antiphospholipid antibodies. In: *Systemic Lupus Erythematosus* (ed. by R. Labita), pp. 813–827. Academic Press, San Diego.
- McNally, T., Mackie, I.J., Machin, S.J. & Isenberg, D.A. (1995) Increased level of β 2 glycoprotein I antigen and β 2 glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. *British Journal of Rheumatology*, **34**, 1031–1036.
- Mandle, R., Colman, R. & Kaplan, A. (1976) Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **73**, 4179–4183.
- Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., Suzuki, T., Yoshida, S. & Koike, T. (1992) Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. *Journal of Immunology*, **148**, 3885–3891.
- Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D.A. & Koike, T. (1994) Anticardiolipin antibodies recognize β 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. *Journal of Experimental Medicine*, **179**, 457–462.
- Matsuura, E., Kobayashi, K., Yasuda, T. & Koike, T. (1998) Antiphospholipid antibodies and atherosclerosis. *Lupus*, **7**, 135–139.
- Mori, T., Takeya, H., Nishioka, J., Gabazza, E.C. & Suzuki, K. (1996) β 2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. *Thrombosis and Haemostasis*, **75**, 49–55.
- Nimph, J., Wurm, H. & Kostner, M. (1985) Interaction of β 2-glycoprotein I with human blood platelets: influences upon the ADP induced aggregation. *Thrombosis and Haemostasis*, **54**, 397–401.
- Nimph, J., Bevers, E.M., Bomans, P.H., Till, U., Wurm, H., Kostner, G.M. & Zwaal, R.F. (1986) Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. *Biochimica et Biophysica Acta*, **884**, 142–149.
- Roubey, R.A.S. (1994) Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' antibodies. *Blood*, **84**, 2854–2867.
- Schousboe, I. (1985) β 2-glycoprotein I: plasma inhibitor of contact activation of the intrinsic blood coagulation pathway. *Blood*, **66**, 1086–1091.
- Schousboe, I. (1988) Inositolphospholipid-accelerated activation of prekallikrein by activated factor XII and its inhibition by beta 2-glycoprotein I. *European Journal of Biochemistry*, **176**, 629–636.
- Schousboe, I. & Rasmussen, M.S. (1995) Synchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by β 2-glycoprotein I and anti- β 2-glycoprotein I. *Thrombosis and Haemostasis*, **73**, 798–804.
- Sheng, Y., Sali, A., Herzog, H., Lahnstein, J. & Krilis, S.A. (1996) Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. *Journal of Immunology*, **157**, 3744–3751.
- Shi, W., Chong, B., Hogg, P. & Chesterman, C. (1993) Anticardiolipin antibodies block the inhibition by β 2-glycoprotein I of

- the factor Xa generating activity of platelets. *Thrombosis and Haemostasis*, 70, 342-345.
- Smirnov, M.S., Triplett, D.T., Comp. P.C., Esmon, N.L. & Esmon, C.T. (1995) On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. *Journal of Clinical Investigation*, 95, 309-316.
- Takeuchi, R., Atsumi, T., Ieko, M., Takeya, H., Yasuda, S., Ichikawa, K., Tsutsumi, A., Suzuki, K. & Koike, T. (2000) Coagulation and fibrinolytic activities in 2 siblings with beta2-glycoprotein I deficiency. *Blood*, 96, 1594-1595.
- Takeya, H., Mori, T., Gabazza, E.C., Kuroda, K., Deguchi, H., Matsuura, E., Ichikawa, K., Koike, T. & Suzuki, K. (1997) Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. *Journal of Clinical Investigation*, 99, 2260-2268.
- Yasuda, S., Tsutsumi, A., Chiba, H., Yanai, H., Miyoshi, Y., Takeuchi, R., Horita, T., Atsumi, T., Ichikawa, K., Matsuura, E. & Koike, T. (2000) β 2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. *Atherosclerosis*, 152, 337-346.